Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) Stock Catapults 32% Though Its Price And Business Still Lag The Industry
Sep 25
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedSep 26, 2025
DataAggregated Company Financials
Companies59
- 7D-3.4%
- 3M44.7%
- 1Y150.7%
- YTD138.5%
Over the last 7 days, the Biotech industry has dropped 4.5%, driven by TransThera Sciences (Nanjing) declining 22%. Over the past 12 months, the industry was up 153%. Looking forward, earnings are forecast to grow by 44% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Sep 2025 | HK$1.1t | HK$68.4b | -HK$13,333,128,226.15 | 48.4x | -83.3x | 16.2x |
| Sun, 24 Aug 2025 | HK$1.1t | HK$62.8b | -HK$13,590,104,940.08 | 57.8x | -81.6x | 17.7x |
| Tue, 22 Jul 2025 | HK$902.3b | HK$63.7b | -HK$12,197,903,611.90 | 39x | -74x | 14.2x |
| Thu, 19 Jun 2025 | HK$717.5b | HK$62.1b | -HK$11,770,540,029.51 | 34.5x | -61x | 11.5x |
| Sat, 17 May 2025 | HK$562.2b | HK$61.6b | -HK$11,850,892,393.57 | 30x | -47.4x | 9.1x |
| Mon, 14 Apr 2025 | HK$501.5b | HK$58.2b | -HK$10,846,605,463.11 | 26.2x | -46.2x | 8.6x |
| Wed, 12 Mar 2025 | HK$450.3b | HK$52.5b | -HK$16,891,468,306.53 | 21.9x | -26.7x | 8.6x |
| Fri, 07 Feb 2025 | HK$372.4b | HK$52.0b | -HK$17,287,227,526.18 | 13.2x | -21.5x | 7.2x |
| Sun, 05 Jan 2025 | HK$364.5b | HK$51.8b | -HK$17,195,281,172.77 | 11x | -21.2x | 7x |
| Tue, 03 Dec 2024 | HK$406.5b | HK$52.1b | -HK$17,313,921,660.76 | 10.8x | -23.5x | 7.8x |
| Thu, 31 Oct 2024 | HK$384.5b | HK$52.8b | -HK$17,770,538,198.25 | 11.3x | -21.6x | 7.3x |
| Sat, 28 Sep 2024 | HK$384.7b | HK$53.0b | -HK$18,430,711,177.10 | 11.9x | -20.9x | 7.3x |
| Mon, 26 Aug 2024 | HK$332.4b | HK$53.5b | -HK$18,888,703,785.07 | 11x | -17.6x | 6.2x |
| Wed, 24 Jul 2024 | HK$322.8b | HK$49.6b | -HK$19,418,195,713.85 | 12.3x | -16.6x | 6.5x |
| Fri, 21 Jun 2024 | HK$332.5b | HK$49.7b | -HK$19,448,990,522.83 | 11.4x | -17.1x | 6.7x |
| Sun, 19 May 2024 | HK$370.2b | HK$49.8b | -HK$19,398,952,876.68 | 12.1x | -19.1x | 7.4x |
| Tue, 16 Apr 2024 | HK$334.7b | HK$49.6b | -HK$19,903,440,471.84 | 11x | -16.8x | 6.8x |
| Thu, 14 Mar 2024 | HK$364.5b | HK$47.3b | -HK$20,348,874,667.32 | 17.8x | -17.9x | 7.7x |
| Sat, 10 Feb 2024 | HK$322.5b | HK$46.8b | -HK$20,190,080,935.32 | 15.6x | -16x | 6.9x |
| Mon, 08 Jan 2024 | HK$376.7b | HK$47.0b | -HK$20,300,331,811.00 | 16.9x | -18.6x | 8x |
| Wed, 06 Dec 2023 | HK$413.2b | HK$47.0b | -HK$20,307,662,700.00 | 18.4x | -20.3x | 8.8x |
| Fri, 03 Nov 2023 | HK$414.7b | HK$45.1b | -HK$18,893,824,560.00 | 13x | -21.9x | 9.2x |
| Sun, 01 Oct 2023 | HK$400.6b | HK$45.0b | -HK$19,138,973,954.00 | 13.9x | -20.9x | 8.9x |
| Tue, 29 Aug 2023 | HK$383.9b | HK$39.2b | -HK$20,777,976,857.00 | 16.1x | -18.5x | 9.8x |
| Thu, 27 Jul 2023 | HK$408.9b | HK$35.6b | -HK$23,402,270,550.00 | 26.7x | -17.5x | 11.5x |
| Sat, 24 Jun 2023 | HK$386.4b | HK$35.5b | -HK$23,392,266,748.00 | 24.1x | -16.5x | 10.9x |
| Mon, 22 May 2023 | HK$427.6b | HK$36.2b | -HK$23,886,097,959.00 | 31x | -17.9x | 11.8x |
| Wed, 19 Apr 2023 | HK$458.8b | HK$37.0b | -HK$24,188,327,593.00 | 18.6x | -19x | 12.4x |
| Fri, 17 Mar 2023 | HK$405.3b | HK$33.1b | -HK$36,313,868,184.00 | 23.2x | -11.2x | 12.3x |
| Sun, 12 Feb 2023 | HK$441.6b | HK$34.8b | -HK$35,220,381,302.00 | 29.1x | -12.5x | 12.7x |
| Tue, 10 Jan 2023 | HK$436.7b | HK$34.8b | -HK$35,156,352,187.00 | 30.3x | -12.4x | 12.6x |
| Thu, 08 Dec 2022 | HK$361.4b | HK$33.5b | -HK$33,746,572,965.00 | 22.6x | -10.7x | 10.8x |
| Sat, 05 Nov 2022 | HK$354.8b | HK$33.3b | -HK$32,007,557,322.00 | 18.7x | -11.1x | 10.6x |
| Mon, 03 Oct 2022 | HK$286.2b | HK$34.0b | -HK$32,533,835,264.00 | 17x | -8.8x | 8.4x |
Price to Earnings Ratio
-8.8x
Current Industry PE
- Investors are optimistic on the Hong Kong Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 9.6x is lower than the industry's current PS ratio of 16.1x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 26% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -1.75% | |
| Healthcare | -2.61% | |
| Biotech | -3.38% | |
| Biotech | -3.38% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 9926 Akeso | HK$135.70 | 3.6% +HK$4.3b | 112.2% | PS45.6x | |
| 9969 InnoCare Pharma | HK$17.70 | 5.0% +HK$1.5b | 216.6% | PS21.6x | |
| 9966 Alphamab Oncology | HK$12.66 | 11.1% +HK$1.2b | 348.9% | PE48.4x | |
| 2629 Mirxes Holding | HK$59.75 | 7.7% +HK$1.1b | n/a | PS95.4x | |
| 2565 PegBio | HK$55.90 | 7.7% +HK$1.1b | n/a | PB56x |
